Project Grant R01HL187582
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $716K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45229, USA
Similar Awards
- The National Heart, Lung and Blood Institute awarded Cincinnati Children's Hospital Medical Center $182,551 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research on de novo lipid synthesis and hematopoietic stem cell (HSC) function. The research investigates how monounsaturated fatty acid (MUFA) synthesis, catalyzed by the enzyme stearoyl-CoA desaturase 1 (SCD1), maintains HSC regenerative capacity by supporting mitochondrial function. The...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded the University of California, San Diego $168,795 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on proteostasis in hematopoietic stem cell development. The project, titled "Proteostasis in Hematopoietic Stem Cell Development," addresses dysfunction in inherited bone marrow failure syndromes by investigating protein homeostasis disruption in...
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the Department of Health and Human Services National Institutes of Health, awarded $753,539 to the University of Cincinnati Sponsored Research Services Division on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of CPNE5 (Copine 5) in cardiovascular barrier dysfunction and septic cardiomyopathy. The research addresses sepsis-induced heart failure through mechanistic study...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $249,000 under the Cardiovascular Diseases Research program (CFDA 93.837) on April 2, 2026, to support research on the role of subpleural fibroblasts in pulmonary fibrosis progression. The funded research investigates idiopathic pulmonary fibrosis (IPF), which begins with scar tissue buildup at the lung edges and advances centrally. The project applies lineage tracing, mouse modeling, and...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1.137883 million on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the dynamics and plasticity of the hematopoietic stem cell niche. The funded work defines niche dynamics and plasticity across development, regeneration, and hematological disease; uncovers the mechanisms regulating these processes; and develops approaches to enhance...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...
- The National Heart, Lung, and Blood Institute awarded $1.175 million to Icahn School of Medicine at Mount Sinai on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate hemogenic mesoderm heterogeneity, regulation, and function in the developing mammalian hematopoietic system. The research, led by Dr. Sturgeon, delineates the molecular and transcriptional mechanisms by which hemogenic mesoderm gives rise to embryonic hematopoietic programs. The work...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $1,818,088 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how postnatal hypoxemia—reduced blood oxygen levels present in cyanotic congenital heart disease—impacts cardiac maturation and surgical recovery outcomes in pediatric patients. The project will examine the interaction between hypoxemia, myocardial immaturity, and postoperative complications through...
- The National Heart, Lung, and Blood Institute awarded The Trustees of The University of Pennsylvania $632,561 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify and optimize signaling pathways that promote the maturation of pre-hematopoietic stem cells into long-term, multi-lineage adult-repopulating hematopoietic stem cells. The research focuses on transforming growth factor beta and bone morphogenetic protein signaling pathways, with emphasis on...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Trustees of Boston University $100,228 on December 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate enhancement of engraftment potential in human hematopoietic stem cells. The research addresses the challenge of preserving hematopoietic stem cell functionality during the ex vivo culture steps required for gene editing therapies. The project employs multi-modal profiling of...